{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:22:42Z","timestamp":1789500162851,"version":"build-2803163510"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To ensure reported laboratory results are of adequate quality, it is paramount that the set analytical performance specifications (APS) are tailored to the intended uses of the measurand. For measurands with a pivotal position in the clinical pathway, APS should be set based on clinical outcome. This paper, written as a result of an outcome-based-APS-summit in Prague, gives practical guidance on how to set outcome-based APS. Two approaches are mentioned with distinct starting points of the required performance (how much clinical misclassification do we allow, and which APS fulfils that premise) or the current performance (what is the effect of the current analytical performance characteristics (APC) on how much misclassification occurs). Importantly, APS should not just be set, but also requires monitoring, which method depends on the utilization of the test in clinical practice. The laboratory can monitor APS for so-called mother-daughter systems, individual analysers or a virtual-analyser system. This paper discusses the pros and cons of these approaches.<\/jats:p>\n                  <jats:p>To highlight the scope of clinically consequential outcomes for which APS can be set and monitored, the Faecal Immunochemical Testing for human haemoglobin (FIT), used for the Dutch Colorectal Cancer Screening programme (CRC-Screening), is used as an example. Here, APS were based on a clinically consequential intermediate outcome, i.e.\u00a0analytically induced variability in colonoscopy referral rate (\u00b10.5\u202f%), and implemented as a virtual analyser system, dividing the APS budget of 10\u202f% equally across four sources of FIT variation: reagent\/calibrator lot variation, sampling buffer lot variation, within-analyser variation, and between-analyser variation.<\/jats:p>","DOI":"10.1515\/cclm-2026-0319","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:56:36Z","timestamp":1789059396000},"source":"Crossref","is-referenced-by-count":1,"title":["The Dutch colon cancer screening programme as an example of adopting indirect-outcome-based analytical performance specifications using a virtual analyser concept"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-990X","authenticated-orcid":false,"given":"Marith","family":"Van Schrojenstein Lantman","sequence":"first","affiliation":[{"name":"SKML , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"De Jong","sequence":"additional","affiliation":[{"name":"Bevolkingsonderzoek Nederland , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Van Der Groep","sequence":"additional","affiliation":[{"name":"Bevolkingsonderzoek Nederland , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien A.","family":"Kemper","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , IJsselland Hospital , Capelle Aan Den IJssel , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"De Groot","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Haematology , ETZ Hospital , Tilburg , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Vossen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Haematology , Zuyderland Medical Center , Sittard-Geleen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mohrmann","sequence":"additional","affiliation":[{"name":"STAR-SHL Medical Diagnostic Centre , GP Laboratory , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"Ten Kate","sequence":"additional","affiliation":[{"name":"Bevolkingsonderzoek Nederland , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke A.M.","family":"Frasa","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Chemistry and Hematology , Jeroen Bosch Hospital , \u2018s-Hertogenbosch , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-669X","authenticated-orcid":false,"given":"Marc H.M.","family":"Thelen","sequence":"additional","affiliation":[{"name":"SKML , Nijmegen , The Netherlands"},{"name":"Department of Laboratory Medicine , Radboud University Medical Center , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091016563367584_j_cclm-2026-0319_ref_001","doi-asserted-by":"crossref","unstructured":"Sandberg, S, Fraser, CG, Horvath, AR, Jansen, R, Jones, G, Oosterhuis, W, et al.. Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European Federation of clinical chemistry and laboratory medicine. Clin Chem Lab Med CCLM 2015;53:833\u20135. https:\/\/doi.org\/10.1515\/cclm-2015-0067.","DOI":"10.1515\/cclm-2015-0067"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_002","doi-asserted-by":"crossref","unstructured":"Ceriotti, F, Fernandez-Calle, P, Klee, GG, Nordin, G, Sandberg, S, Streichert, T, et al.. Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM strategic conference. Clin Chem Lab Med CCLM 2017;55:189\u201394. https:\/\/doi.org\/10.1515\/cclm-2016-0091.","DOI":"10.1515\/cclm-2016-0091"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_003","doi-asserted-by":"crossref","unstructured":"Collet, JP, Thiele, H, Barbato, E, Barth\u00e9l\u00e9my, O, Bauersachs, J, Bhatt, DL, et al.. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","DOI":"10.1093\/eurheartj\/ehaa575"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_004","doi-asserted-by":"crossref","unstructured":"Kilpatrick, ES, Atkin, SL. Using haemoglobin A(1c) to diagnose type 2 diabetes or to identify people at high risk of diabetes. BMJ 2014;348:g2867. https:\/\/doi.org\/10.1136\/bmj.g2867.","DOI":"10.1136\/bmj.g2867"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_005","doi-asserted-by":"crossref","unstructured":"Sacks, DB, Arnold, M, Bakris, GL, Bruns, DE, Horvath, AR, Lernmark, \u00c5, et al.. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2023;69:808\u201368. https:\/\/doi.org\/10.1093\/clinchem\/hvad080.","DOI":"10.1093\/clinchem\/hvad080"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_006","doi-asserted-by":"crossref","unstructured":"Banoo, S, Bell, D, Bossuyt, P, Herring, A, Mabey, D, Poole, F, et al.. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol. 2006;4:S21\u201331. https:\/\/doi.org\/10.1038\/nrmicro1523.","DOI":"10.1038\/nrmicro1523"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_007","doi-asserted-by":"crossref","unstructured":"Schreuders, EH, Ruco, A, Rabeneck, L, Schoen, RE, Sung, JJY, Young, GP, et al.. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637\u201349. https:\/\/doi.org\/10.1136\/gutjnl-2014-309086.","DOI":"10.1136\/gutjnl-2014-309086"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_008","doi-asserted-by":"crossref","unstructured":"Van Schrojenstein Lantman, M, Cobbaert, C, Panteghini, M, Van Berkel, M, Smeets, RL, Van Hellemond, JJ, et al.. Why metrological traceability matters in medical laboratory diagnostics. J\u00a0Appl Lab Med 2026;jfaf203. https:\/\/doi.org\/10.1093\/jalm\/jfaf203.","DOI":"10.1093\/jalm\/jfaf203"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_009","doi-asserted-by":"crossref","unstructured":"Plebani, M, Cadamuro, J, Vermeersch, P, Jovi\u010di\u0107, S, Ozben, T, Trenti, T, et al.. A vision to the future: value-based laboratory medicine. Clin Chem Lab Med CCLM 2024;62:2373\u201387. https:\/\/doi.org\/10.1515\/cclm-2024-1022.","DOI":"10.1515\/cclm-2024-1022"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_010","doi-asserted-by":"crossref","unstructured":"\u00c7ubuk\u00e7u, HC, Vanstapel, F, Thelen, M, Van Schrojenstein Lantman, M, Bernabeu-Andreu, FA, Me\u0161ko Brguljan, P, et al.. APS calculator: a data-driven tool for setting outcome-based analytical performance specifications for measurement uncertainty using specific clinical requirements and population data. Clin Chem Lab Med 2024;62:597-607. https:\/\/doi.org\/10.1515\/cclm-2023-0740.","DOI":"10.1515\/cclm-2023-0740"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_011","doi-asserted-by":"crossref","unstructured":"Van Schrojenstein Lantman, M, Grobben, R, Van Herwaarden, AE, Van Berkel, M, Schaap, J, Thelen, M. To rule-in, or not to falsely rule-out, that is the question: evaluation of hs-cTnT EQA performance in light of the ESC-2020 guideline. Clin Chem Lab Med 2024;62:1158\u201366. https:\/\/doi.org\/10.1515\/cclm-2023-1226.","DOI":"10.1515\/cclm-2023-1226"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_012","doi-asserted-by":"crossref","unstructured":"Loh, TP, Smith, AF, Bell, KJL, Lord, SJ, Ceriotti, F, Jones, G, et al.. Setting analytical performance specifications using HbA1c as a model measurand. Clin Chim Acta Int J Clin Chem 2021;523:407\u201314. https:\/\/doi.org\/10.1016\/j.cca.2021.10.016.","DOI":"10.1016\/j.cca.2021.10.016"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_013","doi-asserted-by":"crossref","unstructured":"Loh, TP, Lord, SJ, Bell, K, Bohn, MK, Lim, CY, Markus, C, et al.. Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: practical considerations applied to COVID-19 testing. Clin Biochem 2021;88:18\u201322. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.11.003.","DOI":"10.1016\/j.clinbiochem.2020.11.003"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_014","unstructured":"Functional Unit Committee. Clinical and analytical performance specifications|EFLM [Internet]. Available from: https:\/\/www.eflm.eu\/site\/who-we-are\/divisions\/science-division\/fu\/c-clinical-and-analytical-performance-specifications [Accessed 5 May 2026]."},{"key":"2026091016563367584_j_cclm-2026-0319_ref_015","doi-asserted-by":"crossref","unstructured":"Horvath, AR, Bossuyt, PMM, Sandberg, S, John, AS, Monaghan, PJ, Verhagen-Kamerbeek, WDJ, et al.. Setting analytical performance specifications based on outcome studies\u00a0\u2013\u00a0is it possible? Clin Chem Lab Med CCLM 2015;53:841\u20138. https:\/\/doi.org\/10.1515\/cclm-2015-0214.","DOI":"10.1515\/cclm-2015-0214"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_016","doi-asserted-by":"crossref","unstructured":"Jones, GRD, Bell, KJL, Ceriotti, F, Loh, TP, Lord, S, Sandberg, S, et al.. Applying the Milan models to setting analytical performance specifications\u00a0\u2013\u00a0considering all the information. Clin Chem Lab Med 2024;62:1531\u20137. https:\/\/doi.org\/10.1515\/cclm-2024-0104.","DOI":"10.1515\/cclm-2024-0104"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_017","doi-asserted-by":"crossref","unstructured":"Thelen, MHM, Van Schrojenstein Lantman, M. When bias becomes part of imprecision: how to use analytical performance specifications to determine acceptability of lot-lot variation and other sources of possibly unacceptable bias. Clin Chem Lab Med 2024;62:1505\u201311. https:\/\/doi.org\/10.1515\/cclm-2023-1303.","DOI":"10.1515\/cclm-2023-1303"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_018","doi-asserted-by":"crossref","unstructured":"Panteghini, M. Redesigning the surveillance of in\u00a0vitro diagnostic medical devices and of medical laboratory performance by quality control in the traceability era. Clin Chem Lab Med CCLM 2023;61:759\u201368. https:\/\/doi.org\/10.1515\/cclm-2022-1257.","DOI":"10.1515\/cclm-2022-1257"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_019","doi-asserted-by":"crossref","unstructured":"Braga, F, Panteghini, M. Defining permissible limits for the combined uncertainty budget in the implementation of metrological traceability. Clin Biochem 2018;57:7\u201311. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.03.007.","DOI":"10.1016\/j.clinbiochem.2018.03.007"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_020","unstructured":"Calleja, J. Parallel processing and maintaining adequate alignment between instruments and methods. Clin Biochem Rev 2008;29:S71\u20137."},{"key":"2026091016563367584_j_cclm-2026-0319_ref_021","doi-asserted-by":"crossref","unstructured":"Jansen, RTP, Cobbaert, CM, Weykamp, C, Thelen, M. The quest for equivalence of test results: the pilgrimage of the Dutch Calibration 2.000 program for metrological traceability. Clin Chem Lab Med 2018;56:1673\u201384. https:\/\/doi.org\/10.1515\/cclm-2017-0796.","DOI":"10.1515\/cclm-2017-0796"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_022","unstructured":"Medical laboratories \u2013 practical guidance for the estimation of measurement uncertainty [ISO\/TS 20914]. Available from: https:\/\/www.iso.org\/cms\/render\/live\/en\/sites\/isoorg\/contents\/data\/standard\/06\/94\/69445.html"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_023","doi-asserted-by":"crossref","unstructured":"Van Schrojenstein Lantman, M, \u00c7ubuk\u00e7u, HC, Boursier, G, Panteghini, M, Bernabeu-Andreu, FA, Milinkovic, N, et al.. An approach for determining allowable between reagent lot variation. Clin Chem Lab Med 2022;60:681\u20138. https:\/\/doi.org\/10.1515\/cclm-2022-0083.","DOI":"10.1515\/cclm-2022-0083"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_024","doi-asserted-by":"crossref","unstructured":"Braga, F, Pasqualetti, S, Aloisio, E, Panteghini, M. The internal quality control in the traceability era. Clin Chem Lab Med CCLM 2021;59:291\u2013300. https:\/\/doi.org\/10.1515\/cclm-2020-0371.","DOI":"10.1515\/cclm-2020-0371"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_025","doi-asserted-by":"crossref","unstructured":"de Jonge, L, Toes-Zoutendijk, E, Koopmann, BDM, Van Schrojenstein Lantman, M, Franken-Van Vorsselen, B, Speijers, C, et al.. Modelling the impact of bias in fecal immunochemical testing on long-term outcomes of colorectal cancer screening. Clin Chim Acta Int J Clin Chem 2024;561:119809. https:\/\/doi.org\/10.1016\/j.cca.2024.119809.","DOI":"10.1016\/j.cca.2024.119809"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_026","doi-asserted-by":"crossref","unstructured":"Braga, F, Infusino, I, Panteghini, M. Performance criteria for combined uncertainty budget in the implementation of metrological traceability. Clin Chem Lab Med CCLM 2015;53:905\u201312. https:\/\/doi.org\/10.1515\/cclm-2014-1240.","DOI":"10.1515\/cclm-2014-1240"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_027","doi-asserted-by":"crossref","unstructured":"Buchta, C, Marrington, R, De la Salle, B, Albar\u00e8de, S, Albe, X, Badrick, T, et al.. Behind the scenes of EQA\u00a0\u2013\u00a0characteristics, capabilities, benefits and assets of external quality assessment (EQA): part III\u00a0\u2013\u00a0EQA samples. Clin Chem Lab Med 2025;63:868\u201378. https:\/\/doi.org\/10.1515\/cclm-2024-1291.","DOI":"10.1515\/cclm-2024-1291"},{"key":"2026091016563367584_j_cclm-2026-0319_ref_028","doi-asserted-by":"crossref","unstructured":"Buchta, C, De la Salle, B, Marrington, R, Aburto Almonacid, A, Albar\u00e8de, S, Badrick, T, et al.. Behind the scenes of EQA\u00a0\u2013\u00a0characteristics, capabilities, benefits and assets of external quality assessment (EQA): part V\u00a0\u2013\u00a0benefits for stakeholders other than participants. Clin Chem Lab Med 2025;63:898\u2013915. https:\/\/doi.org\/10.1515\/cclm-2024-1293.","DOI":"10.1515\/cclm-2024-1293"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0319\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:56:42Z","timestamp":1789059402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0319\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":28,"alternative-id":["10.1515\/cclm-2026-0319"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0319","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}